UNASSIGNED:胃腺癌(STAD)是胃癌的一种主要类型,具有很高的发病率和死亡率。NPRL2,候选抑癌基因,已被证明在各种类型的癌症中具有抗癌作用。因此,对STAD中NPRL2的综合分析可能为胃癌的治疗提供潜在的预后指标和临床靶点.
UNASSIGNED:根据人类蛋白质图谱的数据分析了基因组表达和甲基化,基因表达Omnibus和Oncomine数据库。使用Kaplan-Meier方法进行生存分析,使用来自癌症基因组图谱数据库的数据。使用在线免疫细胞丰度标识符进行免疫相关性分析和对免疫疗法的反应预测。共表达分析,在R,通过逆概率治疗加权方法平衡临床协变量。
UNASSIGNED:NPRL2在STAD中异常下调(P<0.05)。生存分析强调了NPRL2表达与患者临床结局之间的正相关(P<0.05)。基于共表达分析,我们发现NPRL2可能参与上皮-间质转化,胃癌干细胞,STAD对化疗药物的反应性(P<0.05)。此外,功能聚类分析显示NPRL2参与mTOR信号通路,自噬,和氨基酸饥饿反应(调整P<0.05)。此外,在STAD中,NPRL2与肿瘤浸润免疫细胞呈负相关,而与免疫治疗生物标志物呈正相关(P<0.05)。同时,预计NPRL2高表达的患者对免疫治疗的反应更好(P<0.05).最后,基于NPRL2相关基因构建的预后模型可以预测STAD患者的预后(AUC=0.641),风险评分是STAD患者的独立预后因素(HR=4.855,95%CI:2.683~8.785,P<0.001)。
UNASSIGNED:本研究对NPRL2在STAD中的作用和潜在机制进行了全面分析,表明NPRL2是STAD患者生存和免疫治疗反应预测的潜在生物标志物。
UNASSIGNED: Stomach adenocarcinoma (STAD) is a major type of gastric cancer with high morbidity and mortality.
NPRL2, a candidate cancer suppressor gene, has been shown to have anti-cancer effects in various types of cancers. Therefore, comprehensive analyses of
NPRL2 in STAD may provide a potential prognostic marker and clinical target for the management of gastric cancer.
UNASSIGNED: Genomic expression and methylation were analysed based on data from the Human Protein Atlas, Gene Expression Omnibus and Oncomine database. Survival analyses were conducted with the Kaplan-Meier method, using data from The Cancer Genome Atlas database. Immune correlation analyses and prediction of response to immunotherapy were performed using the online Immune Cell Abundance Identifier. Co-expression analyses, functional clustering analyses and construction of a prognostic risk model were conducted in R, with the clinical covariates balanced by the inverse probability treatment weighting method.
UNASSIGNED: NPRL2 was abnormally downregulated in STAD (P<0.05). Survival analysis highlighted a positive association between the expression of NPRL2 and clinical outcomes for patients (P<0.05). Based on co-expression analyses, we found that
NPRL2 may be involved in epithelial-mesenchymal transition, gastric cancer stem cells, and responsiveness to chemotherapeutic agents in STAD (P<0.05). Furthermore, functional clustering analysis revealed that NPRL2 was involved in the mTOR signalling pathway, autophagy, and the amino acid starvation response (adjust P<0.05). In addition, NPRL2 was negatively associated with tumour-infiltrating immune cells while positively associated with immunotherapeutic biomarkers in STAD (P<0.05). Meanwhile, patients with high
NPRL2 expression were predicted to have a better response to immunotherapy (P<0.05). Finally, a prognostic model constructed based on NPRL2-related genes could predict the prognosis of STAD patients (AUC =0.641), and the risk score was an independent prognostic factor for STAD patients (HR =4.855, 95% CI: 2.683-8.785, P<0.001).
UNASSIGNED: The present study provided a comprehensive analysis of the role and potential mechanisms of NPRL2 in STAD, suggesting that NPRL2 is a potential biomarker for the survival and prediction of immunotherapy response in STAD.